Literature DB >> 2509371

Isolation and characterization of a human monoclonal antibody that recognizes epitopes shared by Pseudomonas aeruginosa immunotype 1, 3, 4, and 6 lipopolysaccharides.

A B Lang1, E Fürer, J W Larrick, S J Cryz.   

Abstract

A hybridoma line secreting a human monoclonal antibody (HMAb) capable of recognizing Fisher immunotype (IT) 1, 3, 4, and 6 lipopolysaccharide (LPS) in vitro was isolated. Peripheral blood lymphocytes (PBL) were obtained from volunteers immunized with an experimental Pseudomonas aeruginosa O polysaccharide-toxin A vaccine. PBL-expressing surface antibodies able to bind to P. aeruginosa LPS were isolated by adsorption onto LPS-coated plastic wells. Such PBL were transformed with Epstein-Barr virus. Lymphoblastoid cell lines secreting anti-P. aeruginosa LPS antibodies were identified by an enzyme-linked immunosorbent assay and fused to the F3B6 heteromyeloma line. A hybridoma line producing a HMAb (2-8AH79) able to bind IT-1, IT-3, IT-4, and IT-6 LPS was identified by an enzyme-linked immunosorbent assay. This HMAb was found to bind to the O-polysaccharide regions of IT-1, IT-3, IT-4, and IT-6 LPS, as determined by immunoblotting. By using an immunofluorescence microscopy assay, the cell surfaces of IT-3 and IT-4 bacteria were strongly stained by HMAb 2-8AH79, whereas those of IT-1 and IT-6 bacteria were weakly stained. This HMAb was found to promote the uptake and killing of IT-3 and IT-4 bacteria, but not IT-1 or IT-6 organisms, by human polymorphonuclear leukocytes. Similarly, the passive transfer of HMAb 2-8AH79 to mice afforded significant protection only against a challenge with IT-3 and IT-4 bacteria.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2509371      PMCID: PMC259916          DOI: 10.1128/iai.57.12.3851-3855.1989

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Protective immunity induced in mice by immunization with high-molecular-weight polysaccharide from Pseudomonas aeruginosa.

Authors:  G B Pier; H F Sidberry; J C Sadoff
Journal:  Infect Immun       Date:  1978-12       Impact factor: 3.441

4.  Bacteremia at Boston City Hospital: Occurrence and mortality during 12 selected years (1935-1972), with special reference to hospital-acquired cases.

Authors:  J E McGowan; M W Barnes; M Finland
Journal:  J Infect Dis       Date:  1975-09       Impact factor: 5.226

5.  Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: description of a burned mouse model.

Authors:  D D Stieritz; I A Holder
Journal:  J Infect Dis       Date:  1975-06       Impact factor: 5.226

6.  Lipopolysaccharide and high-molecular-weight polysaccharide serotypes of Pseudomonas aeruginosa.

Authors:  G B Pier; D M Thomas
Journal:  J Infect Dis       Date:  1982-02       Impact factor: 5.226

7.  Type-specific vs. cross-protective vaccination for gram-negative bacterial pneumonia.

Authors:  J E Pennington; E Menkes
Journal:  J Infect Dis       Date:  1981-12       Impact factor: 5.226

8.  Immunoprotective human monoclonal antibodies against five major serotypes of Pseudomonas aeruginosa.

Authors:  S Sawada; T Kawamura; Y Masuho
Journal:  J Gen Microbiol       Date:  1987-12

9.  Resistance to cefamandole: a collaborative study of emerging clinical problems.

Authors:  C C Sanders; R C Moellering; R R Martin; R L Perkins; D G Strike; T D Gootz; W E Sanders
Journal:  J Infect Dis       Date:  1982-01       Impact factor: 5.226

10.  Controlled trial of Pseudomonas immunoglobulin and vaccine in burn patients.

Authors:  R J Jones; E A Roe; J L Gupta
Journal:  Lancet       Date:  1980-12-13       Impact factor: 79.321

View more
  5 in total

1.  Scale-up and optimization of culture conditions of a human heterohybridoma producing serotype-specific antibodies to Pseudomonas aeruginosa.

Authors:  U Schürch; S J Cryz; A B Lang
Journal:  Appl Microbiol Biotechnol       Date:  1992-07       Impact factor: 4.813

2.  Phage display and bacterial expression of a recombinant Fab specific for Pseudomonas aeruginosa serotype O6 lipopolysaccharide.

Authors:  N L Tout; J S Lam
Journal:  Clin Diagn Lab Immunol       Date:  1997-03

3.  Characterization of the Shigella serotype D (S. sonnei) O polysaccharide and the enterobacterial R1 lipopolysaccharide core by use of mouse monoclonal antibodies.

Authors:  J F Viret; U Bruderer; A B Lang
Journal:  Infect Immun       Date:  1992-07       Impact factor: 3.441

4.  A murine model of chronic mucosal colonization by Pseudomonas aeruginosa.

Authors:  G B Pier; G Meluleni; E Neuger
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

5.  A protective human monoclonal antibody directed to the outer core region of Pseudomonas aeruginosa lipopolysaccharide.

Authors:  M Terashima; I Uezumi; T Tomio; M Kato; K Irie; T Okuda; S Yokota; H Noguchi
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.441

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.